23.11.2012 • NewsBob Dudely BPBob DudleyBP

BP to Restructure Oil Production Unit

BP is planning to announce a reorganization of its oil and gas production operations, three sources familiar with the matter said, the second significant restructuring of its main cash generator since the Gulf of Mexico oil spill.

The latest changes will undo some of the measures Chief Executive Bob Dudley imposed in 2010 and are partly intended to free him up from close oversight of day-to-day operations so he can help chart BP's recovery from the disaster which killed 11 men and spilled 5 million barrels of crude into the sea.

BP's shares have failed to recover since the Macondo well was capped, as the company struggles to convince investors that it has a strategy for growth.

Lamar McKay, currently head of BP's U.S. operations, will become head of a new Exploration and Production (E&P) unit, the sources said, a reinstatement of a role that was abolished in 2010, in the wake of the oil spill. BP declined to comment.

Dudley broke up BP's old E&P division into three units on his elevation to CEO to replace Tony Hayward, whose gaffes in during the spill led to his stepping down.

The creation of functional roles for exploration, drilling and operating oil and gas production facilities, was aimed at moving BP away from its traditional decentralised structure of independent business units.

The decentralised model was blamed by analysts and U.S. government investigators for giving managers incentives to put profits before safety.

Dudley has espoused a more centralised model, akin to that adopted by rival ExxonMobil. The chain of command now runs along functional lines, whereas in the past managers of individual fields or refineries had wide rein to run their assets as they saw fit.

Two sources said Dudley was planning to tweak the structure. "The pendulum had moved too far away from decentralisation," one source said.

Also, the existing model, which created extra roles reporting to the CEO, was seen to hinder Dudley's ability to focus on strategic matters.

"There was a sense that Bob had an awful lot on his plate," one source close to the company said.

BP directors agreed on the restructuring some months ago, one source said, but wanted to delay announcing it until it had made further progress with the U.S. authorities on settling investigations around the spill.

The company said last week it would pay $4.5 billion in penalties and plead guilty to criminal misconduct. A U.S. government civil investigation could also lead to fines in excess of $20 billion and two BP engineers face manslaughter charges relating to the rig blast that led to the spill.

Two sources close to the company said it was also mulling possible changes to its safety division, whereby some safety oversight roles functions might be brought back under the control of the managers of operating units.

The sources said the separate chain of command for safety personal slowed down operations.

But a BP insider said the standalone safety division, created in 2010 to signal BP was serious about safety after a series of disasters, would remain intact

 

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.